Company news

Sight Sciences, Inc. news in 2023

Sight Sciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

December 27, 2023

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

December 17, 2023

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

December 7, 2023

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

November 6, 2023

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

October 23, 2023

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

October 18, 2023

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

October 11, 2023

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

October 2, 2023

Sight Sciences Appoints Matt Link as Chief Commercial Officer

September 10, 2023

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

August 2, 2023

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

July 19, 2023

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

July 19, 2023

Sight Sciences Announces Addition of New Director Catherine Mazzacco

June 8, 2023

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical S...

May 22, 2023

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

May 5, 2023

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

May 3, 2023

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

April 19, 2023

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

April 2, 2023

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

March 12, 2023

Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

March 8, 2023

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

February 22, 2023

Sight Sciences Announces 1,000th TearCare® Customer Installation

January 25, 2023

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results

January 8, 2023

Calls in 2023

Decks in 2023